|
|
 |
 |
| Drug Discovery is administered by Osney Media. |
|
|
|
|
 |
 |
| Next Event |
|
|
10th Annual Drug Discovery Leaders Summit
Monday 15th June 2009 to Tuesday 16th June 2009 Fairmont le Montreux Palace, Montreux, Switzerland
|
|
More
|
|
|
|
 |
|
Oxford Global Conferences’ strict delegate screening criteria and one to one meeting selection facility allow you to reach a large number of pre-qualified Drug Discovery decision makers and make the most of your time at the event. |
|
Read More
|
|
|
| Speakers |
 |
|
The 10th Annual Drug Discovery Leaders Summit consists of a unique blend of presentations, panel discussions and one to one business meetings. If you have a cutting edge case study or a thought provoking presentation join us at the event. |
|
Read More
|
|
|
|
|
|
|
|
| Featured Speakers |
|
|
|
Aldermar Degroot,
Translational Scientist, Translational Medicine Group Leader, Astellas
|
 |
|
|
Nicolas Frey,
Global Head of Modelling and Simulation, F. Hoffman-La Roche
|
|
|
|
Philip Hajduk,
Senior Project Leader, Structural Biology and Lead Discovery, Abbott Laboratories
|
|
|
|
John Haurum,
Chief Scientific Officer, Symphogen A/S
|
|
|
|
Jonathon Knowles,
President of Group Research F. Hoffman-La Roche
|
|
|
|
Ismail Kola,
Senior Vice President, Discovery Research, Early Clinical Research and Experimental Medicine, Schering Plough
|
|
|
|
Phil L'Huillier,
Director, Business Management, Cancer Research Technology Limited
|
|
|
|
Jonathon Mason,
Divisional Director, Early Lead Generation and Computational Chemistry, Lundbeck Research
|
|
|
|
Lorenz Mayr,
Executive Director, BioChemical Assay Development & Screening, Novartis
|
|
|
|
Andy Merritt,
Director Discovery Medicinal Chemistry, GlaxoSmithKline
|
|
|
|
Shintaro Nishimura,
Senior Director, Bioimaging, Astellas Japan
|
|
|
|
Philip Oliver,
Associate Director for Global External R&D Europe, Eli Lilly
|
|
|
|
Paul Passier,
Senior Scientist Exploratory Medicine, Astellas
|
|
|
|
Graham Richards,
Former Head of Chemistry Department, Oxford University
|
|
|
|
Hans Guenter Schaefer,
Director, Clinical Pharmacokinetics/Pharmacodynamics, Boehringer Ingeleheim
|
|
|
|
Bernd Seihelmer,
Head Global R&D Risk Management, Bayer Schering
|
|
|
|
Thomas Senderovitz,
Vice President Global Exploratory Development, UCB Pharma SA
|
|
|
|
Ted Torphy,
CSO and Head, External Research & Early Development, Johnson & Johnson
|
|
|
|
Lex Van der Ploeg,
Vice President Basic Research, Site Head Research Laboratories Boston, Merck
|
|
|
|
Chris van Koppen,
Director, Molecular Pharmacology, Schering-Plough Corporation
|
|
|
|
Malcolm Weir,
CEO, Heptares Therapeutics
|
|
|
|
Alan Wilson,
Vice President Drug Metabolism, Pharmacokinetics and Toxicology, Lexicon Pharmaceuticals
|
|
|
|
Ming-Qiang Zhang,
Vice President Research, Biotica Technology Ltd
|
|
|
|
|
|
|
|
|
|
